Look out for the keynote by Richard Francis, CEO of Teva Pharmaceuticals, where he’ll discuss how Teva’s focus on innovation, sustaining its generics powerhouse, and its focus on growth engines is fuelling the company’s Pivot to Growth Strategy to build a rich portfolio of innovative medicines.

In a challenging year for biopharma with companies navigating market uncertainty and an industry-wide deal slump, Teva Pharmaceuticals has uniquely positioned itself with a bold, new Pivot to Growth Strategy that’s showing early progress and beating investor’s expectations. Richard Francis joined as President and CEO one year ago determined to transform Teva from a company with declining margins into one with a rich portfolio of innovative medicines. With a strategy built on four key pillars to deliver on growth engines, step up innovation, sustain its generics powerhouse, and focus the business, Teva is on a strong path forward with significant growth driven by its innovative portfolio and global leadership in generics.

Speakers

Richard Francis

Chief Executive Officer, Teva Pharmaceuticals

As Chief Executive Officer, Richard Francis is leading Teva to a new strategic path for growth by driving great science from the clinic to the patient to provide life-changing medications around the world.

For more, please find the original story source here.